Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canerpaturev - Takara Bio

Next Previous
Drug Profile

Canerpaturev - Takara Bio

Alternative Names: C-REV; HF-10; Msc-2; TBI-1401

Latest Information Update: 28 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ms Science; Nagoya University
  • Developer Takara Bio; University of Utah
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • No development reported Head and neck cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 28 Jan 2023 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Japan (Intratumoural, Injection)
  • 09 Nov 2021 Otsuka Pharmaceutical terminates licensing agreement with Takara Bio for Canerpaturev in Japan
  • 20 Jan 2021 Canerpaturev is still in phase I trial for Pancreatic cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Japan (Otsuka Pharmaceuticals pipeline, January 2021) (NCT03252808)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top